Paolo Tarantino talks emerging therapies, sequencing, and toxicities
— Paolo Tarantino talks emerging therapies, sequencing, and toxicities
by Gregory Laub, Senior Director, Video, MedPage Today
July 7, 2026
• 2 min read
At the American Society of Clinical Oncology (ASCO) meeting, studies focusing on antibody-drug conjugates (ADCs) across multiple breast cancer subtypes highlighted not only the expanding role of these therapies, but also the new challenges of sequencing treatments and managing their unique toxicities.
ADCs have moved from the salvage setting into first-line treatment
Rapid evolution from niche concept to broadly applicable, clinically validated drug class
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway…
CHICAGO — In this video, Pedro C. Barata, MD, MSc, FACP, discusses preliminary safety, dosimetry and pharmacokinetic results from…
Novel approach was well tolerated in combination with neoadjuvant therapy
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
